Neuroleptic malignant syndrome in an AIDS patient: clinical and pathological findings.
Neuroleptic malignant syndrome (NMS) has been recently described following therapy with non strictly neuroleptic drugs that alter dopaminergic function, such as sulpiride and metoclopramide, and might occur more easily in patients with functional or organic brain disorders. We observed an AIDS patient who suffered from NMS following treatment with clotiapine for insomnia and agitation. Two months later, he presented with a similar syndrome following antiemetic treatment with alizapride. On both occasions, the symptoms completely regressed after the administration of dopaminergic and muscle relaxant drugs. The patient died of pneumonia one month after the last episode. The present paper describes the clinical and pathological findings.
Gabellini
A S
AS
Servizio di Neurologia, Ospedale Maggiore, Bologna.
Pezzoli
A
A
De Massis
P
P
Casadei
G
G
Grillo
A
A
Sacquegna
T
T
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000473:pathology; D000328:Adult; D000932:Antiemetics / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000009:adverse effects; D003987:Dibenzothiazepines / Q000009:adverse effects; D015259:Dopamine Agents / Q000627:therapeutic use; D006556:Heroin Dependence / Q000150:complications; D006801:Humans; D008297:Male; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D009459:Neuroleptic Malignant Syndrome / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D011759:Pyrrolidines / Q000009:adverse effects; D013378:Substantia Nigra / Q000473:pathology
D000932:Antiemetics; D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D015259:Dopamine Agents; D009125:Muscle Relaxants, Central; D011759:Pyrrolidines; C033968:alizapride; C084602:clothiapine